Reuters logo
India's Sun Pharma expects 18-20 pct FY13 sales growth
May 30, 2012 / 5:12 AM / in 5 years

India's Sun Pharma expects 18-20 pct FY13 sales growth

MUMBAI, May 30 (Reuters) - India’s Sun Pharmaceutical Industries Ltd expects 18-20 percent sales growth in the current fiscal year that started in April, Managing Director Dilip Shanghvi said in an earnings conference call on Wednesday.

On Tuesday, the company reported an 85 percent jump in quarterly profit to 8.20 billion rupees ($146 million). ($1 = 56.1 Indian rupees) (Reporting by Kaustubh Kulkarni; Editing by Ranjit Gangadharan)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below